Morgan Stanley raised the firm’s price target on Edwards Lifesciences (EW) to $81 from $75 and keeps an Equal Weight rating on the shares. The firm continues to like the MedTech industry setup into Q2 on relative stability in procedure volumes and hospital capital expenditures across the space, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Cautious Outlook for Edwards Lifesciences Amidst TAVR Sales Challenges and Market Share Concerns
- Edwards Lifesciences’ PROGRESS Trial: A Game-Changer for Aortic Stenosis Treatment?
- Edwards Lifesciences Launches MITRIS Valve Study in China: A Potential Market Game-Changer
- Edwards Lifesciences initiated with a Buy at Argus
- Edwards Lifesciences’ SAPIEN X4 Valve Study: A Potential Game-Changer in Heart Valve Treatment